טוען...
HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
BACKGROUND: Patients with non‐small cell lung cancer (NSCLC) harboring activating EGFR mutations are sensitive to epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) but inevitably develop resistance to the inhibitors mostly through acquisition of the secondary T790M mutation. Al...
שמור ב:
| הוצא לאור ב: | Thorac Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley & Sons Australia, Ltd
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7919131/ https://ncbi.nlm.nih.gov/pubmed/33471376 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13839 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|